Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
Paul J. Hampel(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Asher Chanan‐Khan(WinnMed), Tait D. Shanafelt(Mayo Clinic), Amie Fonder, Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Susan L. Slager(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Thomas E. Witzig(WinnMed)
Cited by 63
Related Papers
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Changes in Burnout and Satisfaction With Work-Life Integration in Physicians and the General US Working Population Between 2011 and 2017
|Mayo Clinic Proceedings|2019|903
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727